Celiac Disease Market Size to Reach USD 1404.72 Mn by 2032

According to analysts at Vantage Market Research, the Global Celiac Disease Market size is worth USD 600.2 Million in 2023 and is projected to reach USD 1404.72 Million by 2032, growing at a CAGR (Compound Annual Growth Rate) of 9.9% from 2024 to 2032. Market is driven by increasing prevalence of the disease, rising awareness about gluten intolerance, growing demand for gluten-free products, and advancements in diagnostic tools for early detection.

Market Overview

The increasing incidence of celiac disease worldwide is a significant driver of market growth. More people are being diagnosed with celiac disease due to increased awareness and improved diagnostic skills. For instance, a study conducted by celiac Australia estimates that 360,000 Australians, or around one in every 70 persons, have celiac disease; of those who do, four out of five are not aware they have it. As healthcare systems evolve and understanding of the disease improves, the number of individuals seeking treatment is expected to rise.

While the demand for gluten-free products has surged, the availability of these items can be limited in certain regions, particularly in developing countries. Additionally, gluten-free products often come with a higher price tag, making them less accessible to some consumers. This can hinder adherence to the necessary gluten-free diet for those diagnosed with celiac disease. The high cost and limited selection create gap in the market, highlighting the need for manufacturers to expand their offerings and improve accessibility, which could lead to increased competition and innovation.

Key Takeaways from the Report

• In 2023, North America dominated the market with 36.5% market share. market is driven by the a high rate of diagnosis due to greater awareness and advanced diagnostic tools, particularly in the United States
• Based on the Treatment, Gluten Free Diet category accounted for significant market share of 39.5% in 2023. It is considered the gold standard and the only medically recognized treatment for the condition
• In 2023, Oral route of administration dominated the market with largest market share of 59.8%. Oral administration pertains to the intake of food and medications by mouth, including gluten-free products as well as any prescribed drugs or supplements needed to manage the condition

Top Companies

• Asia Pacific  Amgen
• Anokion SA
• BioLineRx Ltd
• ChemoCentryx Inc
• COUR Pharmaceutical
• F. Hoffmann-La Roche Ltd
• ImmunogenX LLC
• Innovate Biopharmaceuticals
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.